Correlation Between Structure Therapeutics and Replimune
Can any of the company-specific risk be diversified away by investing in both Structure Therapeutics and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Structure Therapeutics and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Structure Therapeutics American and Replimune Group, you can compare the effects of market volatilities on Structure Therapeutics and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Structure Therapeutics with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Structure Therapeutics and Replimune.
Diversification Opportunities for Structure Therapeutics and Replimune
-0.32 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Structure and Replimune is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Structure Therapeutics America and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and Structure Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Structure Therapeutics American are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of Structure Therapeutics i.e., Structure Therapeutics and Replimune go up and down completely randomly.
Pair Corralation between Structure Therapeutics and Replimune
Given the investment horizon of 90 days Structure Therapeutics American is expected to under-perform the Replimune. But the stock apears to be less risky and, when comparing its historical volatility, Structure Therapeutics American is 2.01 times less risky than Replimune. The stock trades about -0.15 of its potential returns per unit of risk. The Replimune Group is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest 1,202 in Replimune Group on September 6, 2024 and sell it today you would earn a total of 115.00 from holding Replimune Group or generate 9.57% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Structure Therapeutics America vs. Replimune Group
Performance |
Timeline |
Structure Therapeutics |
Replimune Group |
Structure Therapeutics and Replimune Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Structure Therapeutics and Replimune
The main advantage of trading using opposite Structure Therapeutics and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Structure Therapeutics position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.Structure Therapeutics vs. Day One Biopharmaceuticals | Structure Therapeutics vs. X4 Pharmaceuticals | Structure Therapeutics vs. Inozyme Pharma | Structure Therapeutics vs. Acumen Pharmaceuticals |
Replimune vs. Nuvalent | Replimune vs. Ventyx Biosciences | Replimune vs. Ascendis Pharma AS | Replimune vs. United Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |